The Sleep Medicine Research Group plans to initiate three crucial research studies on assessing the role of sleep apnea treatment, prognosis of patients after myocardial infarction and prevention of sudden cardiac death and atrial fibrillation recurrence. Important part of the SMED activities will be continuous data analysis from projects where enrollment of patients was already completed. This way can evaluate a rising opportunity to identify a severe risk factors and to eliminate it via a corresponding therapy. The SMED Research Group would like to establish one of the first center capable of monitoring the frequency and appropriate use of technologies for SA treatment. Center of telemonitoring will be established as an integral part of the current Cardiovascular Sleep Research Center and its support will be crucially important to improve the reliability of outcomes of above described sleep research studies.
This research group detected a high prevalence of previously undiagnosed SA in acute myocardial infarction patients. In this population, peak occurrence of MI onset was between 6 AM and noon in SA patients, similar to what is observed in the general population. Considering that this is a group at high risk for heart failure, fatal arrhythmia, recurrent MI and sudden death, treatment of SA may provide an important strategy for secondary prevention. Whether treating SA reduces post-MI morbidity and mortality awaits the findings of randomized controlled trials.